Hollow-fiber bioreactors market to hit $2.33 billion by 2030

The hollow-fiber bioreactors market is projected to grow from $1.5 billion in 2025 to $1.64 billion in 2026, with demand rising in cell-based therapies, personalized medicine and biopharmaceutical production. The market is expected to reach $2.33 billion by 2030 as single-use systems, automation and continuous perfusion technologies gain traction.

Why it matters: - Hollow-fiber bioreactors are becoming more important in biopharmaceutical development, tissue engineering and high-density cell culture. - The market’s projected growth points to stronger demand for scalable manufacturing tools as cell and gene therapies expand. - The report’s forecasts signal where investment and capacity-building may shift in biomanufacturing over the next several years.

What happened: - The Business Research Company released its Hollow-Fiber Bioreactors Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the hollow-fiber bioreactors market will rise from $1.5 billion in 2025 to $1.64 billion in 2026, a 9.3% CAGR. - The market is forecast to reach $2.33 billion by 2030, at a 9.2% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available. - The full market report is also available.

The details: - Hollow-fiber bioreactors use bundles of semi-permeable hollow fibers to create a large surface area for cell growth and product synthesis. - The systems support nutrient, gas and waste exchange while closely simulating physiological conditions. - The platforms are used in biomanufacturing and research for high-density cell cultures, protein production and continuous perfusion processes. - Growth through 2026 has been driven by reliance on conventional cell culture techniques, scalability limits in traditional bioreactors and higher research activity in biopharmaceuticals and tissue engineering. - Reusable bioreactors during early production phases have also supported demand. - The report says future growth will be driven by single-use bioreactor technology, modular and automated setups, and stronger demand for high-throughput protein production. - CRO outsourcing and integration with continuous perfusion and real-time monitoring systems are also expected to support expansion. - Key trends identified in the report include wider use of single-use hollow-fiber bioreactors, more high-density cell culture applications, rising biopharmaceutical protein manufacturing, and a stronger focus on automation and throughput. - The report lists market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables among its 2026 report capabilities.

Between the lines: - Cell-based therapies are creating more need for closed systems that can expand and harvest therapeutic cells consistently. - The report cites the launch of six first-in-class cell and gene therapies in 2023, up from three in 2022, as evidence of that demand. - Personalized medicine is adding another layer of demand because customized treatments require reliable, scalable cell production. - The report cites 16 new personalized treatments for rare diseases approved by the US Food and Drug Administration in 2023, up from six in 2022. - The regional split suggests mature biopharma ecosystems are still driving volume, while faster growth is shifting toward Asia-Pacific.

What's next: - Market growth is expected to continue as single-use systems, automation and continuous perfusion become more common. - Biopharmaceutical developers and contract research organizations are likely to keep investing in higher-throughput and more flexible production setups. - Continued adoption of real-time monitoring and modular bioreactor systems may shape the next phase of product development and manufacturing capacity.

The bottom line: - Hollow-fiber bioreactors are moving from a niche cell culture tool toward a core platform for scalable biologics and cell therapy manufacturing.